Published in Br J Clin Pharmacol on January 01, 2014
Inverse association between hepatitis B virus infection and fatty liver disease: a large-scale study in populations seeking for check-up. PLoS One (2013) 0.88
Drug-induced liver injury: results from the hospital-based Berlin Case-Control Surveillance Study. Br J Clin Pharmacol (2015) 0.82
Assessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS database. World J Hepatol (2014) 0.82
Revisiting the Metabolism and Bioactivation of Ketoconazole in Human and Mouse Using Liquid Chromatography-Mass Spectrometry-Based Metabolomics. Int J Mol Sci (2017) 0.75
Comparative Hepatotoxicity of Fluconazole, Ketoconazole, Itraconazole, Terbinafine, and Griseofulvin in Rats. J Toxicol (2017) 0.75
The possible efficacy of artichoke in fluconazole related hepatotoxicity. Case Reports Hepatol (2014) 0.75
Risk of liver injury after α-glucosidase inhibitor therapy in advanced chronic kidney disease patients. Sci Rep (2016) 0.75
Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med (2002) 11.38
Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol (1993) 7.63
Drug-induced hepatotoxicity. N Engl J Med (2003) 7.11
Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf (2010) 5.80
Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol (1990) 5.66
Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology (2008) 5.45
Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med (2011) 5.13
A 10-year experience with universal health insurance in Taiwan: measuring changes in health and health disparity. Ann Intern Med (2008) 3.80
Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology (2002) 3.64
Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology (2005) 3.52
Cancer risk in patients with pyogenic liver abscess: a nationwide cohort study. Aliment Pharmacol Ther (2012) 2.83
Survival analysis Part III: multivariate data analysis -- choosing a model and assessing its adequacy and fit. Br J Cancer (2003) 2.71
Accuracy of diabetes diagnosis in health insurance claims data in Taiwan. J Formos Med Assoc (2005) 2.70
Outcome and prognostic markers in severe drug-induced liver disease. Hepatology (2005) 2.36
Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology (2010) 2.26
Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl (2004) 1.96
The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology (1989) 1.80
The safety of oral antifungal treatments for superficial dermatophytosis and onychomycosis: a meta-analysis. Am J Med (2007) 1.70
Review article: drug hepatotoxicity. Aliment Pharmacol Ther (2007) 1.60
Hepatic injury during ketoconazole therapy in patients with onychomycosis: a controlled cohort study. Hepatology (1997) 1.54
Secular trends and geographic variations of hepatitis B virus and hepatitis C virus-associated hepatocellular carcinoma in Taiwan. Int J Cancer (2006) 1.40
Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology (2009) 1.35
Review article: Drug-induced liver injury--its pathophysiology and evolving diagnostic tools. Aliment Pharmacol Ther (2011) 1.32
Review article: drug-induced liver injury in clinical practice. Aliment Pharmacol Ther (2010) 1.32
Incidence of bleeding from gastroduodenal ulcers in patients with end-stage renal disease receiving hemodialysis. CMAJ (2011) 1.30
Safety of newly approved drugs: implications for prescribing. JAMA (2002) 1.27
A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs. Br J Clin Pharmacol (1999) 1.26
Effective reduction of gastric cancer risk with regular use of nonsteroidal anti-inflammatory drugs in Helicobacter pylori-infected patients. J Clin Oncol (2010) 1.23
Epidemiology of idiosyncratic drug-induced liver injury. Semin Liver Dis (2009) 1.10
Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality. Ther Clin Risk Manag (2005) 1.08
Terbinafine-induced hepatic failure requiring liver transplantation. Liver Transpl (2007) 1.02
Hepatotoxicity of antifungal agents. Curr Opin Investig Drugs (2005) 0.90
Liver failure and transplantation after itraconazole treatment for toenail onychomycosis. J Eur Acad Dermatol Venereol (2005) 0.86
Increased risk of hospitalization for acute hepatitis in patients with previous exposure to NSAIDs. Pharmacoepidemiol Drug Saf (2010) 0.84
Terbinafine and fulminant hepatic failure. N Engl J Med (1999) 0.83
Risk of liver injury associated with Chinese herbal products containing radix bupleuri in 639,779 patients with hepatitis B virus infection. PLoS One (2011) 0.81
Case-crossover study of hospitalization for acute hepatitis in Chinese herb users. J Gastroenterol Hepatol (2008) 0.77
Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med (2011) 5.13
HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A (2005) 3.82
MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest (2012) 3.46
Comprehensive analysis of the independent effect of twist and snail in promoting metastasis of hepatocellular carcinoma. Hepatology (2009) 3.42
Short-term use of serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding. Am J Psychiatry (2014) 2.88
Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med (2008) 2.66
Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol (2009) 2.56
Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics (2006) 2.25
Surgical Resection Versus Radiofrequency Ablation for Single Hepatocellular Carcinoma ≤ 2 cm in a Propensity Score Model. Ann Surg (2016) 2.20
Renal failure in patients with hepatocellular carcinoma and ascites undergoing transarterial chemoembolization. Liver Int (2009) 2.09
Surgical resection versus transarterial chemoembolization for BCLC stage C hepatocellular carcinoma. J Surg Oncol (2015) 2.09
Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol (2013) 2.08
Long contiguous stretches of homozygosity in the human genome. Hum Mutat (2006) 2.07
Critical illness-related corticosteroid insufficiency in cirrhotic patients with acute gastroesophageal variceal bleeding: risk factors and association with outcome*. Crit Care Med (2014) 2.07
Phospholipase A2 and cyclooxygenase 2 genes influence the risk of interferon-alpha-induced depression by regulating polyunsaturated fatty acids levels. Biol Psychiatry (2009) 1.93
Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology (2003) 1.92
Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage: a randomized trial. Hepatology (2004) 1.78
A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei Integrated Scoring System. J Hepatol (2010) 1.77
Model for end-stage liver disease score to serum sodium ratio index as a prognostic predictor and its correlation with portal pressure in patients with liver cirrhosis. Liver Int (2007) 1.66
Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology (2002) 1.64
Differential mechanism and prognostic impact of diabetes mellitus on patients with hepatocellular carcinoma undergoing surgical and nonsurgical treatment. Am J Gastroenterol (2004) 1.63
Nonpeptic ulcer, nonvariceal gastrointestinal bleeding in hemodialysis patients. Am J Med (2013) 1.60
Correlation and comparison of the model for end-stage liver disease, portal pressure, and serum sodium for outcome prediction in patients with liver cirrhosis. J Clin Gastroenterol (2007) 1.60
Endoscopic submucosal dissection for gastric epithelial tumors: a multicenter study in Taiwan. J Formos Med Assoc (2009) 1.59
A randomized trial of endoscopic treatment of acute gastric variceal hemorrhage: N-butyl-2-cyanoacrylate injection versus band ligation. Hepatology (2006) 1.57
A core competence-based objective structured clinical examination (OSCE) in evaluation of clinical performance of postgraduate year-1 (PGY₁) residents. J Chin Med Assoc (2011) 1.57
Is the corrected-creatinine model for end-stage liver disease a feasible strategy to adjust gender difference in organ allocation for liver transplantation? Transplantation (2007) 1.56
Spinal microglia initiate and maintain hyperalgesia in a rat model of chronic pancreatitis. Gastroenterology (2011) 1.55
Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics (2010) 1.51
Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome. J Allergy Clin Immunol (2012) 1.51
Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome. J Allergy Clin Immunol (2011) 1.47
Asymmetric dimethylarginine (ADMA) determines the improvement of hepatic endothelial dysfunction by vitamin E in cirrhotic rats. Liver Int (2011) 1.46
Characteristics of autoimmune hepatitis in Taiwan: the 11 years' experiences of a medical center. Zhonghua Yi Xue Za Zhi (Taipei) (2002) 1.45
HCV NS5A interacts with p53 and inhibits p53-mediated apoptosis. Oncogene (2002) 1.43
Chronic thalidomide administration enhances vascular responsiveness to vasopressin in portal-systemic collaterals of bile duct-ligated rats. J Chin Med Assoc (2009) 1.42
Selecting a short-term prognostic model for hepatocellular carcinoma: comparison between the model for end-stage liver disease (MELD), MELD-sodium, and five cancer staging systems. J Clin Gastroenterol (2009) 1.42
Magnetic resonance angiography in reversible cerebral vasoconstriction syndromes. Ann Neurol (2010) 1.42
Green tea polyphenol decreases the severity of portosystemic collaterals and mesenteric angiogenesis in rats with liver cirrhosis. Clin Sci (Lond) (2014) 1.41
Uncompromised treatment efficacy in elderly patients with hepatocellular carcinoma: a propensity score analysis. Medicine (Baltimore) (2014) 1.41
Chronic inhibition of nitric oxide increases the collateral vascular responsiveness to vasopressin in portal hypertensive rats. J Hepatol (2004) 1.41
Methimazole alleviates hepatic encephalopathy in bile-duct ligated cirrhotic rats. J Chin Med Assoc (2006) 1.40
Secular trends and geographic variations of hepatitis B virus and hepatitis C virus-associated hepatocellular carcinoma in Taiwan. Int J Cancer (2006) 1.40
Sepsis worsening vascular hyporeactivity of the superior mesenteric artery in portal vein-ligated rats. J Chin Med Assoc (2010) 1.39
Effects of norepinephrine and acetylcholine on portal-systemic collaterals of common bile duct-ligated cirrhotic rat. J Gastroenterol Hepatol (2005) 1.38
Immunoglobulin G antibody against Helicobacter pylori is an accurate test for atrophic gastritis. J Chin Med Assoc (2010) 1.37
Mechanisms in mediating the anti-inflammatory effects of baicalin and baicalein in human leukocytes. Eur J Pharmacol (2003) 1.34
Life-threatening hemobilia caused by hepatic artery pseudoaneurysm: a rare complication of chronic cholangitis. World J Gastroenterol (2003) 1.32
Taxifolin ameliorates cerebral ischemia-reperfusion injury in rats through its anti-oxidative effect and modulation of NF-kappa B activation. J Biomed Sci (2005) 1.32
Incidence of bleeding from gastroduodenal ulcers in patients with end-stage renal disease receiving hemodialysis. CMAJ (2011) 1.30
Selecting an optimal staging system for hepatocellular carcinoma: comparison of 5 currently used prognostic models. Cancer (2010) 1.30
A comparison of prognosis between patients with hepatitis B and C virus-related hepatocellular carcinoma undergoing resection surgery. World J Surg (2011) 1.29
Comparison of surgical resection and transarterial chemoembolization for hepatocellular carcinoma beyond the Milan criteria: a propensity score analysis. Ann Surg Oncol (2011) 1.28
Performance status in patients with hepatocellular carcinoma: determinants, prognostic impact, and ability to improve the Barcelona Clinic Liver Cancer system. Hepatology (2013) 1.28
Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients. Gastroenterology (2006) 1.22
Spider angiomas in patients with liver cirrhosis: role of vascular endothelial growth factor and basic fibroblast growth factor. World J Gastroenterol (2003) 1.15
Increasing trend of the incidence of esophageal squamous cell carcinoma, but not adenocarcinoma, in Taiwan. Cancer Causes Control (2009) 1.14
Evaluation of the anti-inflammatory activity of zhankuic acids isolated from the fruiting bodies of Antrodia camphorata. Planta Med (2004) 1.13
Survival rates are comparable after radiofrequency ablation or surgery in patients with small hepatocellular carcinomas. Clin Gastroenterol Hepatol (2010) 1.12
Effects of a 10-week weight control program on obese patients with schizophrenia or schizoaffective disorder: a 12-month follow up. Psychiatry Clin Neurosci (2008) 1.12